Novel small molecules for treating NASH
Novel candidates for NASH: Novel thiourea derivatives bind to RORα protein which leads to suppression of lipid accumulation in hepatocytes
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Others
- Production method
- Available
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- nash, metabolic disease, small molecule, rorα activator
- Category
- Medicines
Seoul National University R&DB Foundation
- Verified Certificate
-
2
Product name | Novel small molecules for treating NASH | Certification | - |
---|---|---|---|
Category | Medicines | Material | - |
Keyword | nash , metabolic disease , small molecule , rorα activator | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | South Korea | Stock | 100000 |
Supply type | Available | HS code | - |
Product Information
Technology Overview
• Exacerbation of non-alcoholic steatohepatitis (NASH) is associated with mitochondrial dysfunction and a homeostatic imbalance
• Retinoic acid receptor-related orphan receptor α (RORα) enhances oxygen consumption rate and expression of genes associated with mitochondrial quality control
• Novel thiourea derivatives directly bind to RORα protein and increase transcriptional activity which leads to suppression of lipid accumulation in hepatocytes
Patent Pending
Country | Application number | Filing date (yyyy.mm.dd) | Status |
PCT | PCT-KR2022-017924 | 2022.11.15 | Unpublished |
Paper
Lee, Mi-Ock, et al. “RORα suppresses interleukin-6-mediated hepatic acute phase response”. Sci Rep. 2019 Aug 13;9(1):11798.
Park, Hyeung-Geun, et al. “Enantioselective Synthesis of Chiral α‐Alkylthiomalonates via a Phase‐Transfer‐Catalyzed α‐Sulfenylation of α‐Alkylmalonates”. Asian J. Org. Chem. 2019, 8, 1732–1739.
- Product Info Attached File
B2B Trade
Price (FOB) | Negotiable | transportation | Negotiation Other |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Others | Shipping time | Negotiable |
Seoul National University R&DB Foundation
-
2
- President
- Jaeyoung KIM
- Address
- Kwanak-ro 1, Gwanak-gu, Seoul, Korea
- Product Category
- Other Analyzers
- Year Established
- 2003
- No. of Total Employees
- 101-500
- Company introduction
-
- Main Markets
-
South Korea
- Main Product
Related Products
NOVA Eye
![syringe](https://web.tradekorea.com/product/881/2116881_02/Medicine_for_dentin_hypersensitivity_2.png)
Medicine for dentin hypersensitivity
![BioDesign](https://web.tradekorea.com/product/642/2118642_02/BioDesign_Protein_drug_design_platform_2.jpg)
BioDesign_Protein drug design platform
NOVA Liver
NOVA SlimX